Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
24.06. | Cosmos Health begins US manufacturing with DolCas Biotech | 3 | Investing.com | ||
24.06. | Cosmos Health Inc.: Cosmos Health Enters U.S. Market with Strategic Made-in-America Manufacturing, Mitigating Tariff Risks; Executes Agreement with New Jersey-Based DolCas Biotech | 297 | GlobeNewswire (Europe) | CHICAGO, June 24, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
24.06. | Cosmos Health startet US-Produktion mit DolCas Biotech | 3 | Investing.com Deutsch | ||
03.06. | Cosmos Health Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
15.05. | Cosmos Health Inc.: RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven | 913 | GlobeNewswire (Europe) | CHICAGO, May 15, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
15.05. | Cosmos Health Inc.: Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven | 333 | GlobeNewswire (Europe) | CHICAGO, May 15, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
COSMOS HEALTH Aktie jetzt für 0€ handeln | |||||
15.05. | Cosmos Health Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
07.05. | Cosmos Health Inc.: Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units | 339 | GlobeNewswire (Europe) | CHICAGO, May 07, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
07.05. | Cosmos Health Inc. - 8-K, Current Report | 2 | SEC Filings | ||
06.05. | Cosmos Health erhält NASDAQ-Fristverlängerung für Compliance | - | Investing.com Deutsch | ||
06.05. | Cosmos Health granted Nasdaq compliance extension | 1 | Investing.com | ||
06.05. | Cosmos Health Inc.: Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq | 290 | GlobeNewswire (Europe) | CHICAGO, May 06, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
30.04. | Cosmos Health CEO boosts stake with $526,000 share purchase | 1 | Investing.com | ||
30.04. | Cosmos Health CEO erhöht Beteiligung durch Aktienkauf im Wert von 526.000 US-Dollar | 2 | Investing.com Deutsch | ||
30.04. | Cosmos Health Inc.: Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 | 337 | GlobeNewswire (Europe) | CHICAGO, April 30, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
16.04. | Cosmos Health Inc.: Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million | 333 | GlobeNewswire (Europe) | CHICAGO, April 16, 2025, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor... ► Artikel lesen | |
15.04. | Cosmos Health Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
09.04. | Cosmos Health sichert Vertrag für Antiseptika-Produktion | 1 | Investing.com Deutsch | ||
09.04. | Cosmos Health secures deal for antiseptic drug production | 2 | Investing.com | ||
09.04. | Cosmos Health Inc.: Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L | 456 | GlobeNewswire (Europe) | CHICAGO, April 09, 2025 ("Cosmos Health" or the "Company')
, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVO NORDISK | 56,87 | +2,32 % | BERENBERG stuft NOVO NORDISK auf 'Hold' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Novo Nordisk mit einem Kursziel von 610 dänischen Kronen auf "Hold" belassen. Nach der ereignislosen ADA-Konferenz (American... ► Artikel lesen | |
PFIZER | 21,365 | +2,89 % | Bristol Myers Squibb, Pfizer Announce Direct-to-patient Option For Eliquis | NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) and Pfizer (PFE) Thursday announced a direct-to-patient option for purchasing their blood thinner medicine, Eliquis through the partnership's... ► Artikel lesen | |
NOVARTIS | 99,48 | +1,38 % | Milliarden für Aktionäre: Novartis hebt Prognose an und startet Mega-Rückkaufprogramm | © Foto: © 2024 Novartis AGDank starker Quartalszahlen hebt Novartis die Gewinnprognose an und belohnt Anleger mit einem Aktienrückkauf im Volumen von bis zu 10 Milliarden US-Dollar. Die Aktie schnellt... ► Artikel lesen | |
AURORA CANNABIS | 4,270 | +6,35 % | BRISANTE Meldung setzt Aurora Cannabis Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
CANOPY GROWTH | 1,066 | +10,70 % | Canopy Growth: Buy, Sell, or Hold in July 2025? | ||
MERCK & CO | 69,60 | +2,50 % | Veeva Systems: Merck Commits to Veeva Vault CRM | Deep application provides foundation for commercial execution
PLEASANTON, Calif., July 21, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Merck (NYSE: MRK), known... ► Artikel lesen | |
ELI LILLY | 660,60 | +0,87 % | Eli Lilly: Warten auf Impulse | In den letzten Wochen zeigte die Aktie eines der bedeutendsten Pharmaunternehmen der Welt auffallend wenig Bewegung Den vollständigen Artikel lesen ... ► Artikel lesen | |
HALO COLLECTIVE | 0,010 | 0,00 % | Waters Corporation Buys Halo Labs | WASHINGTON (dpa-AFX) - Waters Corporation (WAT), an analytical instruments and software firm, said on Wednesday that it has acquired Halo Labs, a company focused on specialized imaging technologies... ► Artikel lesen | |
TILRAY BRANDS | 0,660 | +14,31 % | Tilray stock pops 15%: should you sell TLRY shares into the strength? | ||
TEVA | 13,800 | -1,08 % | Israeli institutional investors bet on Teva | ||
VERTEX PHARMACEUTICALS | 398,60 | +1,67 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis | All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement... ► Artikel lesen | |
INNOCAN PHARMA | 0,128 | -1,16 % | FDA Hammer! CBD-Studie mit riesigen Auswirkungen! | ||
ABBOTT LABORATORIES | 106,10 | -0,36 % | Dividendenbekanntmachungen (15.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5058 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4059 EUR ARCOSA INC US0396531008 0,05... ► Artikel lesen | |
ARZNEIWERK AG VIDA | 0,300 | -36,97 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 30.06.2025 | The following instruments on XETRA do have their last trading day on 30.06.2025Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 30.06.2025ISIN NameDE000A3EX3G0 GORE German Office... ► Artikel lesen | |
CRONOS GROUP | 1,857 | +4,09 % | High Tide schließt mit Cronos Group Inc. eine Vereinbarung über Wandelschuldverschreibungen im Wert von 30 Millionen $ ab | CALGARY, AB, und TORONTO, ON, 16. Juli 2025 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), das
erfolgreiche, auf den Einzelhandel fokussierte... ► Artikel lesen |